Loading...

Alexa Fluor® 700 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_Alx700_041106
C57BL/6 mouse splenocytes stained with CD8 (clone 53-6.7) Alexa Fluor® 700 (filled histogram) or rat IgG2a, κ Alexa Fluor® 700 isotype control (open histogram).
  • 53-6dot7_Alx700_041106
    C57BL/6 mouse splenocytes stained with CD8 (clone 53-6.7) Alexa Fluor® 700 (filled histogram) or rat IgG2a, κ Alexa Fluor® 700 isotype control (open histogram).
See Alexa Fluor® 700 spectral data
Cat # Size Price Quantity Check Availability Save
100729 25 µg 76€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100730 100 µg 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 700 under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 700 has a maximum emission of 719 nm when it is excited at 633nm / 635nm. Prior to using Alexa Fluor® 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Adams NM et al. 2018. Immunity. 48(6):1172-1182 . PubMed
  2. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  3. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
  4. Zhang YS, et al. 2018. Cancer Biol Ther. 19:735. PubMed
  5. Zhu X et al. 2019. Cell reports. 27(4):1205-1220 . PubMed
  6. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  7. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  8. Li C, et al. 2018. Cell. 174:285. PubMed
  9. Wang F, et al. 2018. Carcinogenesis. 39:889. PubMed
  10. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  11. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  12. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  13. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  14. Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed
  15. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  16. Kim MY, et al. 2017. Plant Biotechnol J. 1.729166667. PubMed
  17. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  18. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  19. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  20. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  21. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed
  22. Qiao J, et al. 2019. Cancer Cell. 35:901. PubMed
  23. Bronisz–Budzynska I, et al. 2019. Skelet Muscle. 9:22. PubMed
  24. Alexander RK, et al. 2020. eLife. 9:e54090.. PubMed
  25. Shimizu K, et al. 2020. Molecular Cell. 77(5):937-950.e6.. PubMed
  26. Resch TK, et al. 2018. Sci Rep. 0.722916667. PubMed
  27. Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed
  28. Engelbertsen D, et al. 2013. Arterioscler Thromb Vasc Biol. 33:637. PubMed
  29. McPhee C, et al. 2013. J Immunol. 191:4581. PubMed
  30. Bunn P, et al. 2014. J Immunol. 192:3709. PubMed
  31. Carty S, et al. 2014. PLoS One. 9:106659. PubMed
  32. Herz J, et al. 2015. J Exp Med. 212: 1153 - 1169. PubMed
  33. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  34. Solaymani-Mohammadi S, et al. 2016. J Leukoc Biol. 99: 475 - 482. PubMed
  35. Ma C, et al. 2016. Nature. 531:253-257. PubMed
  36. Engel I, et al. 2016. Nat Immunol. 10.1038/ni.3437. PubMed
  37. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  38. Rossnagl S, et al. 2016. PLoS Biol. 14: 1002562. PubMed
  39. Pérol L, et al. 2016. Nat Commun. 7:13027. PubMed
  40. Panciera T, et al. 2016. Cell Stem Cell. 19:725-737. PubMed
  41. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  42. Nakagawa P, et al. 2017. Physiol Rep. 10.14814/phy2.13084. PubMed
  43. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  44. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  45. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  46. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  47. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  48. Mender I, et al. 2020. Cancer Cell. 38(3):400-411.e6. PubMed
  49. Hamaidi I, et al. 2020. Cell Metabolism. 32(3):420-436.e12. PubMed
  50. Hall JA, et al. 2020. Cell Metabolism. 32(4):665-675.e6. PubMed
  51. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  52. Biancur DE, et al. 2020. Cell Metabolism. 33(1):199-210.e8. PubMed
  53. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  54. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  55. Liu X, et al. 2021. eLife. 0.416666666666667. PubMed
  56. Noah AC, et al. 2020. J Appl Physiol (1985). 473:128. PubMed
  57. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  58. Penkert RR, et al. 2020. Obesity (Silver Spring). 1631:28. PubMed
  59. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  60. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  61. Panea C, et al. 2021. Commun Biol. 4:913. PubMed
  62. Reguzova A, et al. 2020. Vaccines (Basel). 8:. PubMed
  63. Chen J, et al. 2021. Sci Adv. 7:. PubMed
  64. Zhang XW, et al. 2021. Oncoimmunology. 10:1920739. PubMed
  65. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  66. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  67. Wilhelm J, et al. 2021. J Control Release. 329:353. PubMed
  68. Wabitsch S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1166. PubMed
  69. Yan C, et al. 2022. NPJ Precis Oncol. 6:6. PubMed
  70. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  71. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  72. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  73. Almeida AS, et al. 2021. Bio Protoc. 11:e4012. PubMed
  74. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  75. Wang Y, et al. 2021. Cancer Res. 81:174. PubMed
  76. Fite BZ, et al. 2021. Sci Rep. 11:927. PubMed
  77. Yang Y, et al. 2021. Sci Adv. 7:eabf6290. PubMed
  78. Georgiadou A, et al. 2022. Elife. 11:. PubMed
  79. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  80. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  81. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  82. Pitsch J, et al. 2021. Ann Neurol. 89:666. PubMed
  83. Sobecki M, et al. 2021. Nat Commun. 12:4700. PubMed
  84. Gawish R, et al. 2022. Elife. 11:. PubMed
  85. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  86. Li H, et al. 2022. Cell Rep Med. 3:100554. PubMed
  87. Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed
  88. Ye M, et al. 2022. Nat Nanotechnol. 17:880. PubMed
  89. Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed
  90. Kennedy EM, et al. 2022. Nat Commun. 13:5907. PubMed
  91. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  92. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  93. Chen RJ, et al. 2022. iScience. 25:105595. PubMed
  94. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  95. Liu Z, et al. 2022. Cancer Commun (Lond). 42:971. PubMed
  96. Abdelnabi MN, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:1269. PubMed
  97. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  98. Balood M, et al. 2022. Nature. 611:405. PubMed
  99. Edwards CL, et al. 2023. J Clin Invest. 133: . PubMed
  100. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  101. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  102. Cui B, et al. 2023. Int Immunopharmacol. 114:109541. PubMed
  103. Abu Hejleh AP, et al. 2023. Int J Tryptophan Res. 16:11786469231153111. PubMed
  104. Zimmerman SM, et al. 2022. Oncogene. 41:4983. PubMed
  105. Schroeter CB, et al. 2022. J Neuroinflammation. 19:270. PubMed
  106. Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed
  107. Roussel-Queval A, et al. 2023. STAR Protoc. 4:102119. PubMed
  108. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  109. Falahat R, et al. 2023. Nat Commun. 14:1573. PubMed
  110. Comeau K, et al. 2023. Bio Protoc. 13:e4679. PubMed
RRID
AB_493702 (BioLegend Cat. No. 100729)
AB_493703 (BioLegend Cat. No. 100730)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org
Go To Top Version: 3    Revision Date: 06.27.2014

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account